PPARG: A Promising Therapeutic Target in Breast Cancer and Regulation by Natural Drugs

Figure 3

PPARG expression and the prognosis of BC. The KM survival curve of the PPARG gene in TCGA data is shown, wherein diverse groups were analyzed utilizing the log-rank test. HR (High exp.) represents the HR between the high and low expression groups. An HR > 1 indicates that the gene is a risk factor (higher expression is associated with poorer prognosis), whereas an HR < 1 indicates that the gene is a protective factor (higher expression is associated with better prognosis). The 95% CI represents the range of HR values with a certain level of certainty. Median time represents the time at which the survival rates of the high expression and low expression groups intersect at 50% (i.e., the median survival time). (a) Kaplan–Meier analysis of overall survival for ER+ BC in TCGA, PPARG gene is a protective factor in ER+ BC. (b) Kaplan–Meier analysis of overall survival for ER− BC in TCGA, survival of patients with ER− BC is not associated with the expression level of PPARG. (c) Kaplan–Meier analysis of overall survival for ER+ BC in Kaplan–Meier plotter, PPARG gene is a protective factor in ER+ BC. (d) Kaplan–Meier analysis of overall survival for ER− BC in in Kaplan–Meier plotter, survival of patients with ER− BC is not associated with the expression level of PPARG.

(a)

(b)

(c)

(d)